Patent 9,447,077 Landscape: Scope and Claims for US Dry Eye Method Using High-Purity Formula I Compound
Executive summary: U.S. Patent 9,447,077 covers a US method-of-treatment claim for dry eye disease using a specific isolated “Formula I” compound in a composition administered to a subject, with enforceable claim limits tied to drug substance purity (>90%, with narrower dependent thresholds >98%) and stereochemistry (≥95% S-enantiomer), plus a salt form restriction (sodium salt in a dependent claim). The patent’s practical enforcement zone is therefore the intersection of (i) dry eye indication, (ii) Formula I compound identity, (iii) purity/single-enantiomer specifications, and (iv) salt form for the narrowest claim. Competitor freedom-to-operate hinges less on generic “dry eye” labeling and more on whether the marketed API or an approved ANDA/505(b)(2) product can meet the same Formula I identity and purity/enantiomer/salt features under the claimed administration method.
What does US patent 9,447,077 claim for dry eye treatment and high-purity Formula I compounds?
Core claim coverage (independent claim 1):
- Claim type: Method of treating disease.
- Indication: Dry eye disease in a subject in need.
- Act of treatment: Administering an effective amount of a composition.
- Composition limitation: The composition comprises an isolated compound of Formula I or a pharmaceutically acceptable salt.
- Material limitation (purity): The compound comprises a purity > about 90%.
Immediate scope implication: A product can infringe if it is used to treat dry eye and the administered compound:
- is the Formula I compound (or a salt),
- is isolated as claimed (claims typically target an API prepared and characterized to the claimed spec),
- meets the >90% purity threshold.
Because claim 1 is a method-of-use claim, infringement depends on use (prescription, labeling, or actual treatment) of a product containing the claimed material specification, not just the mere existence of a formulation in the supply chain.
How do dependent claims narrow the purity and stereochemistry coverage?
Claim 2 (purity threshold uplift):
- Compound purity is > about 98%.
Claim 3 (enantiomeric enrichment):
- Compound comprises at least about 95% of an S-enantiomer.
Claim 4 (salt form):
- Compound is a sodium salt.
Scope layering:
- Claim 1 provides the broadest material spec (purity >90%).
- Claim 2 narrows to ultra-high purity (>98%).
- Claim 3 adds a stereochemical restriction that is not necessarily implied by high purity (you can be >98% total purity but still have a racemic or partially enriched enantiomer ratio).
- Claim 4 adds a salt identity limitation. Even if the base compound is correct and purity is correct, a non-sodium salt may avoid claim 4.
Enforcement leverage: If a competitor’s ANDA/505(b)(2) product uses the same Formula I core but has different purity/enantiomer/salt specs, they may fall outside dependent claims while still risking claim 1 depending on whether their API meets >90% purity.
Which specific features drive infringement risk under claim 1 (purity, Formula I identity, and salt)?
Three infringement gates:
- Formula I identity
- The claim is limited to an isolated compound of Formula I.
- Without the Formula I structural definition in the question text, the analysis focuses on claim mechanics: competitors must confirm whether their API is the same Formula I compound or an equivalent salt/derivative captured by “pharmaceutically acceptable salt” language.
- Purity requirement (>90%)
- Claim 1 requires greater than about 90% purity.
- For a competitor, the practical question is whether their marketed API, as manufactured and tested under their quality system, meets the >90% spec in a way that aligns with how courts interpret “purity” (typically tied to assay characterization, impurities profile, and validated test methods).
- Salt form
- Claim 1 includes “pharmaceutically acceptable salt thereof.”
- Claim 4 narrows to “sodium salt.”
- This means claim 4 is a subset of claim 1. If the API is a non-sodium salt, claim 4 can be avoided while still potentially falling within claim 1.
Materiality of “isolated”
- The claim says the composition comprises an isolated compound.
- In practice, that tends to target an API obtained and purified to meet defined specs, not a crude extract or unpurified mixture.
How strong is the patent estate around purity and stereochemistry for dry eye therapies?
Claim-style strength: spec-and-use combination
- Patents that hinge on tight API specs often narrow design-around options but create a new litigation axis: quality testing evidence.
- Because claim 1 is anchored to >90% purity, the patentee can pursue arguments that infringement occurs where accused products meet that threshold.
Dependent claim leverage
- Claim 2 (>98% purity) gives the patentee a higher benchmark for products that use high-grade material (common in commercial manufacturing where high assay purity is the norm).
- Claim 3 (≥95% S-enantiomer) targets a common design-around: use a different enantiomeric ratio to avoid stereochemical limitation. If the competitor sells a single-enantiomer product, they can fall under this claim.
- Claim 4 (sodium salt) limits the narrowest path. If the competitor uses a different salt, claim 4 may be avoided even if the base compound and purity specs are met.
Net effect: The overall enforcement value is strongest against competitors whose commercial API matches both the Formula I identity and typical manufacturing specs that exceed 90% purity and/or provide S-enantiomer enrichment and sodium salt form.
What patent landscape typically surrounds US 9,447,077: formulation, method-of-use, and related API claims?
The claim set you provided is explicitly method-of-treatment with API spec limitations, not an ophthalmic formulation claim on its face. In the US patent universe, a common pattern is that a dry-eye active ingredient family is protected by:
- upstream compound-of-Formula claims (composition of matter),
- downstream method-of-use claims by indication,
- additional enantiomer/salt/purity claims,
- and often formulation or device patents for ophthalmic delivery.
How this maps to 9,447,077:
- US 9,447,077 likely functions as an indication-specific method patent with quality-control specs layered on top of the active ingredient identity.
- If other patents exist in the same family, they may cover:
- base molecule and stereochemistry,
- synthetic intermediates and processes,
- salt selection and polymorphs,
- and formulation parameters for ocular use.
Practical risk: Even if a competitor avoids 9,447,077 by adjusting purity or enantiomer ratio, they can still face composition-of-matter or other method patents that cover dry eye treatment more broadly or with different spec limits.
When does US 9,447,077 lose exclusivity and what does that mean for generic or 505(b)(2) entry?
A full exclusivity and expiration analysis requires the patent’s:
- filing date,
- earliest priority,
- claimed expiration type (including any PTA),
- and any listed terminal disclaimer,
none of which are provided in the prompt.
Because the question provides only the claim text, a complete and accurate exclusivity timeline cannot be produced here.
What Orange Book status would matter for 9,447,077, and what is the likely regulatory hook?
A complete Orange Book and regulatory linkage analysis also depends on identifying:
- the NDA/ANDA/505(b)(2) product tied to the “Formula I” active ingredient,
- the relevant active ingredient(s) and listed patents,
none of which are present in the prompt.
What can be said from claim scope alone:
- The patent is a method-of-use claim for dry eye disease using an identified active.
- In the Orange Book context, method-of-use patents are typically listed for the NDA product where that use is claimed.
What Paragraph IV litigation risks exist for this claim type?
Because the claim is a method-of-treatment claim, Paragraph IV certifications would typically be relevant where an ANDA or 505(b)(2) applicant seeks approval for a product intended to treat the claimed indication using a product containing the claimed active ingredient spec.
Litigation trigger mechanics for spec-limited method patents:
- The key contested issues tend to be:
- whether the accused product’s active ingredient is the claimed Formula I compound (identity),
- whether it meets the purity >90% or other thresholds (assay and impurity profile),
- whether the accused use corresponds to “dry eye disease” and the label or actual use meets the method claim.
How do you design around claims with purity and enantiomer limits for dry eye?
Design-around levers keyed to the claim language:
- Purity threshold manipulation
- Avoid claim 1 by using a compound with ≤ about 90% purity, but this is often commercially impractical because ocular drugs typically require stringent impurity and assay specs.
- Avoid claim 2 by ensuring purity does not exceed about 98%. This is also uncommon because suppliers commonly exceed such thresholds.
- Enantiomer ratio change
- Avoid claim 3 by supplying a compound with < about 95% S-enantiomer.
- This can be feasible if the competitor can use a different enantiomeric mixture without losing efficacy and regulatory acceptance.
- Salt selection
- Avoid claim 4 by using a non-sodium pharmaceutically acceptable salt.
- Claim 1 still covers non-sodium salts, so this is only a dependent-claim avoidance strategy.
- Avoiding “isolated compound of Formula I”
- A competitor could attempt to avoid exact chemical identity, but that changes the active ingredient and typically triggers a different IP and regulatory path.
Net: Purity and enantiomer specs shift design-around from “formulation alone” to active ingredient manufacturing and characterization.
How does US 9,447,077 compare with other dry eye IP (steroid, cyclosporine, lifitegrast, secretagogues)?
A direct comparison requires identifying the “Formula I” compound structure, which the prompt omits. Without knowing whether the Formula I compound corresponds to a known class (e.g., integrin antagonist, immunomodulator, omega-1 receptor agonist), it’s not possible to map the claim’s competition set or enumerate specific competing patent estates.
Key patent-scope conclusions from the provided claims
- Claim 1 is a dry eye method-of-use claim tied to a Formula I isolated compound with purity >90%.
- Claim 2 increases the purity bar to >98%, covering higher-grade API supply chains.
- Claim 3 restricts to a predominantly S-enantiomer API (≥95% S).
- Claim 4 restricts salt form to a sodium salt.
- The enforceable boundary is the combination of indication + drug identity + quantitative API specs.
Key Takeaways
- US 9,447,077 is enforceable on a method-of-treating dry eye disease theory using a Formula I isolated compound.
- The decisive novelty in your claim excerpt is the quantitative API purity threshold (>90%), with narrower dependent thresholds (>98% purity, ≥95% S-enantiomer, and sodium salt).
- The strongest infringement exposure is for competitors whose commercial API is high purity and/or S-enantiomer enriched, and whose salt form is sodium or otherwise still captured by “pharmaceutically acceptable salt.”
- Litigation will likely center on active ingredient characterization evidence (assay/impurities, stereochemical composition) and use/labeling for dry eye treatment.
FAQs
1) Does US 9,447,077 cover non-sodium salts?
Claim 1 covers “pharmaceutically acceptable salt thereof,” so non-sodium salts can still fall under claim 1. Claim 4 is the specific sodium salt-dependent limitation.
2) If a generic product uses the same active ingredient but has 85% purity, is it outside claim 1?
Claim 1 requires purity greater than about 90%, so an accused product would need to be above that threshold to meet the claim limitation.
3) Can a competitor avoid claim 3 by switching from S-enriched to racemic material?
If the S-enantiomer content is below about 95%, the product would not meet the claim 3 stereochemistry limitation, though claim 1 may still apply if purity and identity match.
4) What evidence matters most for proving infringement on a purity-limited method claim?
Analytical and QC records tying accused API lots to purity and impurity profiles that are comparable to the patent’s “purity” requirement.
5) Does this patent cover formulation buffers, viscosity agents, or delivery systems?
From the provided claim text, coverage is not framed as a formulation composition claim; it is a method-of-use claim keyed to administration of a composition containing the specified isolated Formula I compound with defined purity and (in dependent claims) stereochemistry and salt.
References
- U.S. Patent No. 9,447,077.
